Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.
Full description
Approximately 340 therapy-naïve MS patients with relapsing-remitting form of the disease will be randomized to receive Avonex alone or Avonex plus methylprednisolone (MP). Patients will receive MP as 500 mg po for 3 days every month or matching placebo. The patients are followed on a 3-monthly basis for 4 years with disability as the primary parameter of efficacy over that time.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Informed consent
- Relapsing remitting MS according to Poser criteria or McDonell criteria and naïve to therapy
- Disability EDSS score of 4.0 or less at baseline
- Clinical activity as defined by at least one relapse in the last year
Exclusion criteria
- Relapse in the month prior to enrolment
- Treatment with immunosuppressive drugs for MS
- History of major depression
- Former severe reactions to corticosteroids
- Pregnant women
- Diabetes mellitus, and drug or alcohol dependency
- Known or suspected allergy to trial products
Trial design
Primary purpose
Allocation
Interventional model
Masking
345 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal